RYTM News and Press, Rhythm Pharmaceuticals Inc. From 09/25/19

Rhythm Pharmaceuticals (NASDAQ: RYTM ) will announce an update on its R&D programs, genetic sequencing efforts and patient finding initiatives at its R&D event in New York City. More news on: Rhythm Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

-- Four new MC4R pathway obesity indications added to Phase 2 Basket Study and enrolling patients  -- -- Genetic sequencing of 13,567 individuals with severe obesity yields 11.7 percent (1,584 individuals) who have a rare genetic variant within MC4R pathway eligible for Phase 2 ...

In early August, Rhythm Pharmaceuticals ( RYTM ) reported results from two phase 3 trials of its drug setmelanotide in rare genetic forms of obesity. The release of the results was met with a short term rally, but the stock found itself trading back at baseline within a few sessions. Throu...

Rhythm Pharmaceuticals (NASDAQ: RYTM ) has been granted orphan drug designation for setmelanotide in treatment of Bardet-Biedl syndrome. More news on: Rhythm Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

-- Plan to expand ongoing Phase 2 Basket Study with four additional rare indications -- -- Sequenced nearly 14,000 people with early-onset, severe obesity; Yield suggests potential significant opportunity for setmelanotide across new indications -- -- Rhythm to host and webcast R&D...

BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that company management will participate in two invest...

RYTM stock is making a solid move after Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) announced positive results from two Phase 3 clinical trials evaluating setmelanotide. Key Development When biotech companies receive positive news with regards to any of their medicines that are under devel...

Rhythm Pharmaceuticals (NASDAQ: RYTM ) +29%  on positive late-stage setmelanotide data . More news on: Rhythm Pharmaceuticals, Inc., Guardant Health, Inc., Weight Watchers International, Inc., Stocks on the move, Read more ...

Thinly traded Rhythm Pharmaceuticals (NASDAQ: RYTM ) is up  38%  premarket on increased volume following its announcement of positive results from two Phase 3 clinical trials evaluating setmelanotide for the treatment of pro-opiomelanocortin (POMC) and leptin receptor (LEPR) defi...

-- Both studies met primary and all key secondary endpoints with statistically significant and clinically meaningful results in reductions of weight and hunger -- -- Rhythm on track to complete rolling NDA submission to the FDA for both POMC and LEPR deficiency obesities in 4Q19 or 1Q...